ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Ampac, Noramco in fine chemicals pact

by Rick Mullin
March 19, 2018 | APPEARED IN VOLUME 96, ISSUE 12

Noramco and the contract manufacturer Ampac Fine Chemicals have formed a partnership to produce controlled substances for use in treating addiction, abuse prevention, and attention deficit hyperactivity disorder. Noramco’s output will be supplemented by the former Boehringer Ingelheim plant in Petersburg, Va., that Ampac acquired in 2016. Ampac is “the first company we have found that integrates well with Noramco’s operations and strategic focus,” Noramco CEO James Mish says.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment